Swiss Group

Nov 18, 2024 | smw.ch | Swiss Group

Swiss Society of Medical Oncology, Swiss Society of Hematology, Swiss Group for Clinical Cancer Research. Supplementum 283: Abstracts of the Swiss Oncology & Hematology Congress (SOHC) . Swiss Med Wkly [Internet]. 2024 Nov. 18 [cited 2024 Nov. 18];154(11):4289. Available from: https://smw.ch/index.php/smw/article/view/4289

Apr 10, 2024 | trialbulletin.com | Swiss Group

OverviewAbout 10-20% of all individuals with breast cancer have a so-called triple-negative tumor (TNBC). This type of breast cancer has a particularly unfavorable course and a higher mortality rate compared to other forms of breast cancer. Research studies show that it is important for individuals with TNBC to achieve a so-called pathologic complete response (pCR) to treatment.

Dec 8, 2023 | ejcancer.com | Swiss Group |Kantonsspital St. Gallen

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Nov 20, 2023 | smw.ch | Swiss Group

Swiss Society of Medical Oncology, Swiss Society of Hematology, Swiss Group for Clinical Cancer Research. Supplementum 274: Abstracts of the Swiss Oncology & Hematology Congress (SOHC). Swiss Med Wkly [Internet]. 2023 Nov. 20 [cited 2023 Nov. 20];153(11):3469. Available from: https://smw.ch/index.php/smw/article/view/3649

Jun 19, 2023 | nature.com | Jacobien R. Hilberink |Thomas Pabst |Saskia K. Klein |Georg Stussi |Markus G. Manz |Sabine Blum | +2 more

AbstractTreatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The impact of performance status, comorbidities, and physical functioning on survival is not well defined for patients treated with hypomethylating agents.